| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 2 (2013) |
Articles |
Toxicity of trabectedin-based combinations in the treatment of different malignant tumors |
|
| 卷 15, 编号 4 (2013) |
Articles |
The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer |
|
| 卷 16, 编号 3 (2014) |
Articles |
Avastin in clinical chemotherapy of malignant tumors |
|
| 卷 16, 编号 2 (2014) |
Articles |
Prognostic significance of dynamics of biochemical markers of neuroendocrine tumors during treatment with biotherapy |
|
| 卷 17, 编号 4 (2015) |
Articles |
Modern possibilities of targeted therapy in metastatic colorectal cancer |
|
| 卷 17, 编号 3 (2015) |
Articles |
Experience of use of everolimus and long-acting somatostatin analogues combination in highly differentiated (G1-G2) neuroendocrine tumors |
|
| 卷 17, 编号 3 (2015) |
Articles |
Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer |
|
| 卷 18, 编号 1 (2016) |
Articles |
BRCA-associated ovarian cancer (the experience of the Chemotherapy Department in N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of Russia) |
(Rus)
|
| 卷 18, 编号 1 (2016) |
Articles |
Lanreotide for the treatment of patients with disseminated high-grade neuroendocrine tumors: the experience of application in case of unsatisfactory tolerability of octreotide |
(Rus)
|
| 卷 19, 编号 3 (2017) |
Articles |
The experience with the application of first-line chemotherapy regimen with EDP-M (etoposide + doxorubicin + cisplatin + mitotane) in patients with advanced adrenocortical carcinoma in the Russian Federation |
(Rus)
|
| 卷 20, 编号 3 (2018) |
Articles |
The first experience of immunotherapy application of ipilimumab in combination with chemotherapy of small-cell lung cancer in the Russian population. Analysis of the combined data of two centers, participating in the multicenter randomized phase III study СА 184-156 |
(Rus)
|
| 卷 21, 编号 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
